L-692,429 vs hGHRH(1-32)NH2
Head-to-head comparison of L-692,429 (L-692,429) and hGHRH(1-32)NH2 (Human growth hormone-releasing factor (1-32) amide) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | L-692,429 | hGHRH(1-32)NH2 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Full Name | L-692,429 | Human growth hormone-releasing factor (1-32) amide |
| Molecular Weight | N/A | N/A |
| Half-Life | unknown / study-dependent | 5-15 minutes |
| Amino Acids | N/A | 32 |
| Typical Dose | 0.03-0.1 mg/kg | 0.1-1 mcg/kg |
| Route | Oral | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 30 | 50 |
| Research Status | Pre-clinical | Clinical Research |
L-692,429 Benefits
- ✓potent GHSR agonism
- ✓oral bioactivity in models
- ✓validates ghrelin pathway
- ✓useful research probe
hGHRH(1-32)NH2 Benefits
- ✓GH pulse induction
- ✓core-sequence testing
- ✓receptor signaling studies
- ✓protease-resistance comparisons
L-692,429 Dosing
0.03-0.1 mg/kg in early studies|single oral or short-course research dosing|serial GH sampling recommended
hGHRH(1-32)NH2 Dosing
0.1-1 mcg/kg SC or IV bolus|acute GH-response testing with timed blood draws|pulsatile dosing in receptor studies
L-692,429 Side Effects
- ⚠increased appetite
- ⚠glucose intolerance
- ⚠transient prolactin changes
hGHRH(1-32)NH2 Side Effects
- ⚠headache
- ⚠flushing
- ⚠injection-site irritation
Research Overview
L-692,429
L-692,429 was important in early GH secretagogue research because it showed that nonpeptide molecules could trigger robust GH release. It remains a classic tool compound for studying receptor-mediated GH pulsatility and appetite signaling.
hGHRH(1-32)NH2
Human GHRF(1-32)NH2 is used in basic and translational studies to evaluate how the active N-terminal region of GHRH drives pituitary hormone release. It helps define the lower bound of sequence length needed for meaningful biological activity.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.